Year: 2025
Type: article
Study design: Observational Study
Abstract: Background and Objectives: Cryoballoon ablation is a well-established therapy for atrial fibrillation (AF), enabling pulmonary vein isolation (PVI) using a single-shot technique. The two primary systems—Medtronic Arctic Front and the newer Boston Scientific POLARx—differ in design and performance characteristics, but few direct comparisons exist. This study aimed to compare the biophysical parameters and mid-term outcomes of the POLARx and Arctic Front cryoballoon systems. Materials and Methods: In a retrospective analysis of 200 patients who underwent cryoballoon ablation for paroxysmal or persistent AF, patients were grouped by ablation system: POLARx (n = 107) and Arctic Front (n = 93). Key parameters including nadir balloon temperatures, time to reach −40 °C, procedure duration, dose area product (DAP), complication rates, and recurrence of AF were assessed. Results: The POLARx system achieved significantly lower nadir temperatures in all pulmonary veins compared to Arctic Front (left superior PV: −57.6 ± 5.0 °C vs. −50.1 ± 5.7 °C, p < 0.001). Time to reach −40 °C was also shorter with POLARx (left superior PV: 23.3 ± 7.3 s vs. 33.3 ± 11.5 s, p < 0.001). Despite these advantages, procedure time was longer in the POLARx group (64.7 ± 14.8 min vs. 51.6 ± 19.7 min, p < 0.001). AF recurrence at 11.8 months was similar (33.6% in POLARx vs. 39.8% in Arctic Front, p = 0.93). Phrenic nerve palsy occurred in 5.0% (POLARx) and 4.3% (Arctic Front), with no cases of cardiac tamponade. Conclusions: While both systems demonstrated similar efficacy and safety, POLARx was associated with superior cooling kinetics and biophysical performance.
Source: Medicina
Authors: Kaspars Kupics, Raivis Bricis, Kristine Jubele, Ieva Ansaberga, Oskars Kalējs, Andrejs Erglis
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,654
OpenAlex ID: W4415565235